Skip to content

Circular RNA and Chemerin in Breast Cancer Patient

Circular RNA and Chemerin in Blood of Breast Cancer Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05771337
Enrollment
80
Registered
2023-03-16
Start date
2023-10-31
Completion date
2025-12-31
Last updated
2023-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

This study aimed to evaluate the role of serum chemerin as a biomarker of breast cancer. and To investigate the diagnostic value of hsa\_circ\_0001785 (Circ-ELP3) and hsa\_circ\_100219 (Circ-FAF1) in serum samples of breast cancer patients to find out whether these circRNAs can utilize as a diagnostic and prognostic biomarker for human breast cancer assessment and make Correlation between serum chemerin levels , serum Circ-FAF1 , serum CircELP3 and classical tumor markers (CEA + CA15-3). andTo elucidate if there is a difference between metastatic and non-metastatic cases as regard serum chemerin levels, serum Circ-FAF1 or Circ-ELP3.

Detailed description

Breast cancer is the most common cancer among women and despite advances in therapy over the past few decades, drug resistance, recurrence, metastasis and the heterogeneity of the cancer continue to be a problem in successful management of the diseases(Hong et al ,2019) . Circular RNAs (CircRNAs) are single-stranded, covalently closed RNA molecules that are ubiquitous across species ranging from viruses to mammals(Zhou et al 3 .,2020). circRNAs can be divided into two categories including coding and noncoding circRNAs(Li et al., 2019) A new subtype of RNAs is circular RNAs, single-strand RNA molecules with less than 100 to more than 4,000 nucleotides (Lu et al., 2016) and a covalently closedloop structure. These molecules are produced through a backsplicing mechanism, in which the downstream 5'-end of the splice donor joins the upstream 3'-end splice acceptor and forms a product with a circular structure (wang et al., 2017). Chemerin is a leukocyte chemoattractant widely expressed in many tissues and is known to recruit innate leukocytes. Recently, more and more studies focus on the relationship between chemerin and cancers and found that chemerin acts an essential role in cancers.(Shin et al,2018) Chemerin expression is different depending on the tumor type (Zhang Y et al, 2013) the clinical significance of chemerin in breast cancer has been only reported by a very limited number of studies (EL Sagheer et al,2018).

Interventions

DIAGNOSTIC_TESTblood sample

blood sample

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* histopathological diagnosis of breast cancer

Exclusion criteria

* history of other types of cancers * history of HIV * history of any therapeutic interventions in form of chemo or hormonal therapy before specimen collection

Design outcomes

Primary

MeasureTime frameDescription
measure chemerin and Circular RNA in breast cancer patients2 yearsTo elucidate if there is a difference between metastatic and non-metastatic cases as regard serum chemerin levels, serum Circ-FAF1 or Circ-ELP3.

Contacts

Primary Contactsandy nashat sorial
sandybsbsa@yahoo.com01200693648
Backup Contactabdelhaleem ali abdelhaleem

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026